A Study of AMG 337 in Subjects With Advanced Solid Tumors

Status:
Completed

Trial end date:
2016-12-01

Target enrollment:

Participant gender:

First in human, open-label, sequential dose escalation and expansion study of AMG 337 in subjects with advanced solid tumors.

Phase 1

Amgen